1. Phylogeny  
   BMPR2 is an evolutionarily conserved type II receptor in the transforming growth factor‐β (TGF‐β) superfamily and is a member of the serine/threonine kinase family found in all vertebrates. Its orthologs are broadly present across species, and it shares significant sequence and structural similarity with related receptors such as activin receptor type IIA (ACVR2A) and activin receptor type IIB (ACVR2B), yet BMPR2 is distinguished by a long cytoplasmic tail not present in those paralogues (duffhuesUnknownyeardikep. pages 1-3, gomez‐puerto2019bonemorphogeneticprotein pages 2-4).
2. Reaction Catalyzed  
   BMPR2 functions as a serine/threonine kinase that catalyzes the transfer of a phosphate group from ATP onto specific hydroxyl groups of serine or threonine residues present in its substrates. In the canonical BMP signaling pathway, BMPR2 phosphorylates its associated type I receptors, which then autophosphorylate further before phosphorylating receptor‐regulated SMADs, thereby initiating downstream transcriptional responses (barnes2016bonemorphogenicprotein pages 1-5).
3. Cofactor Requirements  
   The catalytic activity of BMPR2 is dependent on ATP as a phosphate donor and requires the presence of divalent metal ions, most commonly Mg²⁺, to support efficient phosphoryl transfer during the kinase reaction (gomez‐puerto2019bonemorphogeneticprotein pages 8-9).
4. Substrate Specificity  
   BMPR2 exhibits substrate specificity for serine/threonine residues located in the GS domain of type I BMP receptors as well as in the C-terminal SXS motif of receptor‐regulated SMAD proteins (SMAD1, SMAD5, and SMAD8). This kinase preferentially phosphorylates these substrates upon formation of heteromeric complexes with type I receptors, thereby ensuring specific propagation of the BMP signal (gomez‐puerto2019bonemorphogeneticprotein pages 5-6).
5. Structure  
   BMPR2 is organized into several distinct domains. Its N‐terminal extracellular region is cysteine‐rich and contains multiple N‐linked glycosylation sites—most notably at asparagine residues that enhance ligand binding—which is critical for stabilizing its interaction with BMP ligands such as BMP2 and BMP7 (lowery2014nlinkedglycosylationof pages 3-4). This domain is followed by a single transmembrane helix that anchors the receptor in the plasma membrane. The intracellular region harbors a serine/threonine kinase domain containing conserved catalytic motifs such as the activation loop and C‐helix, and it terminates in an unusually long C‐terminal tail that is unique among BMP type II receptors and may mediate additional regulatory interactions (guo2022crystalstructuresof pages 1-2, duffhuesUnknownyeardikep. pages 4-5).
6. Regulation  
   BMPR2 activity is regulated by several mechanisms. Post‐translational modification by N‐linked glycosylation of its extracellular domain enhances ligand binding and receptor stability (lowery2014nlinkedglycosylationof pages 3-4). Upon BMP ligand binding, BMPR2 forms heteromeric receptor complexes with type I receptors, a process that is essential for triggering both the canonical SMAD signaling cascade and non‐SMAD pathways such as the p38MAPK cascade (gomez‐puerto2019bonemorphogeneticprotein pages 2-4). In addition, the receptor is subject to regulation via receptor trafficking, internalization, and degradation, and mutations that disrupt proper receptor complex assembly or intracellular trafficking lead to reduced signaling capacity and altered downstream pathway activation (hiepen2019bmpr2actsas pages 22-24).
7. Function  
   BMPR2 plays a central role in mediating bone morphogenetic protein (BMP) signaling by binding BMP ligands—including BMP7 and BMP2, and to a lesser extent BMP4—and forming receptor complexes with type I receptors, which in turn phosphorylate and activate receptor‐regulated SMAD transcription factors. This canonical signaling pathway regulates gene expression programs involved in cell proliferation, differentiation, and apoptosis. Furthermore, BMPR2 can also initiate non‐SMAD signaling cascades such as the p38MAPK pathway. In addition to its critical role in skeletal development and adipogenesis induction (e.g., by GDF6), BMPR2 is predominantly expressed in pulmonary arterial endothelial cells where its proper function is essential to maintain vascular homeostasis; mutations in BMPR2 are known to be the primary genetic drivers of both familial pulmonary arterial hypertension (PAH) and a significant subset of idiopathic cases (barnes2016bonemorphogenicprotein pages 1-5, frump2018bmpr2mutationsand pages 1-2, song2005increasedsusceptibilityto pages 9-10).
8. Other Comments  
   Recent chemical biology efforts have led to the discovery of highly potent and BMPR2‐selective kinase inhibitors discovered via DNA‐encoded chemical library screening, offering novel avenues for therapeutic intervention in diseases associated with overactive or dysregulated BMP signaling (modukuri2023discoveryofhighly pages 1-2). Additionally, a wide spectrum of BMPR2 mutations, many of which result in loss‐of‐function, has been documented; these mutations exhibit incomplete penetrance in familial PAH and contribute to disease pathogenesis by impairing receptor trafficking, complex formation, and subsequent downstream signaling (teichertkuliszewska2006bonemorphogeneticprotein pages 1-3, duffhuesUnknownyeardikep. pages 13-13). Inhibitors specifically targeting BMPR2 have not been extensively characterized compared to those affecting type I BMP receptors; nevertheless, modulation of BMPR2 activity remains a highly active area of preclinical research with significant implications for the treatment of pulmonary vascular diseases (hiepen2019bmpr2actsas pages 46-47).
9. References  
   • barnes2016bonemorphogenicprotein pages 1-5  
   • barnes2016bonemorphogenicprotein pages 21-23  
   • duffhuesUnknownyeardikep. pages 1-3  
   • duffhuesUnknownyeardikep. pages 14-14  
   • duffhuesUnknownyeardikep. pages 4-5  
   • dunmore20204pbarestoressignaling pages 21-26  
   • frump2018bmpr2mutationsand pages 1-2  
   • gomez‐puerto2019bonemorphogeneticprotein pages 1-2  
   • gomez‐puerto2019bonemorphogeneticprotein pages 2-4  
   • gomez‐puerto2019bonemorphogeneticprotein pages 5-6  
   • guo2022crystalstructuresof pages 1-2  
   • lowery2014nlinkedglycosylationof pages 3-4  
   • hiepen2019bmpr2actsas pages 22-24  
   • hiepen2019bmpr2actsas pages 1-2  
   • hiepen2019bmpr2actsas pages 46-47  
   • long2015selectiveenhancementof pages 1-2  
   • song2005increasedsusceptibilityto pages 9-10  
   • teichertkuliszewska2006bonemorphogeneticprotein pages 1-3  
   • modukuri2023discoveryofhighly pages 1-2

References

1. (barnes2016bonemorphogenicprotein pages 1-5): Jarrod W. Barnes, Elif T. Kucera, Liping Tian, Noël E. Mellor, Nina Dvorina, William W. Baldwin, Micheala A. Aldred, Carol F. Farver, Suzy A. A. Comhair, Metin Aytekin, and Raed A. Dweik. Bone morphogenic protein type 2 receptor mutation-independent mechanisms of disrupted bone morphogenetic protein signaling in idiopathic pulmonary arterial hypertension. American Journal of Respiratory Cell and Molecular Biology, 55:564-575, Oct 2016. URL: https://doi.org/10.1165/rcmb.2015-0402oc, doi:10.1165/rcmb.2015-0402oc. This article has 31 citations and is from a peer-reviewed journal.
2. (barnes2016bonemorphogenicprotein pages 21-23): Jarrod W. Barnes, Elif T. Kucera, Liping Tian, Noël E. Mellor, Nina Dvorina, William W. Baldwin, Micheala A. Aldred, Carol F. Farver, Suzy A. A. Comhair, Metin Aytekin, and Raed A. Dweik. Bone morphogenic protein type 2 receptor mutation-independent mechanisms of disrupted bone morphogenetic protein signaling in idiopathic pulmonary arterial hypertension. American Journal of Respiratory Cell and Molecular Biology, 55:564-575, Oct 2016. URL: https://doi.org/10.1165/rcmb.2015-0402oc, doi:10.1165/rcmb.2015-0402oc. This article has 31 citations and is from a peer-reviewed journal.
3. (duffhuesUnknownyeardikep. pages 1-3): G Sanchez Duffhues. Di ke, p. ten.(2020). Unknown journal, Unknown year.
4. (duffhuesUnknownyeardikep. pages 14-14): G Sanchez Duffhues. Di ke, p. ten.(2020). Unknown journal, Unknown year.
5. (duffhuesUnknownyeardikep. pages 4-5): G Sanchez Duffhues. Di ke, p. ten.(2020). Unknown journal, Unknown year.
6. (dunmore20204pbarestoressignaling pages 21-26): Benjamin J. Dunmore, XuDong Yang, Alexi Crosby, Stephen Moore, Lu Long, Christopher Huang, Mark Southwood, Eric D. Austin, Amer Rana, Paul D. Upton, and Nicholas W. Morrell. 4pba restores signaling of a cysteine-substituted mutant bmpr2 receptor found in patients with pulmonary arterial hypertension. American Journal of Respiratory Cell and Molecular Biology, 63:160-171, Aug 2020. URL: https://doi.org/10.1165/rcmb.2019-0321oc, doi:10.1165/rcmb.2019-0321oc. This article has 26 citations and is from a peer-reviewed journal.
7. (frump2018bmpr2mutationsand pages 1-2): Andrea Frump, Allison Prewitt, and Mark P. de Caestecker. bmpr2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 grover conference series). Pulmonary Circulation, 8:1-12, Apr 2018. URL: https://doi.org/10.1177/2045894018765840, doi:10.1177/2045894018765840. This article has 49 citations.
8. (gomez‐puerto2019bonemorphogeneticprotein pages 1-2): Maria Catalina Gomez‐Puerto, Prasanna Vasudevan Iyengar, Amaya García de Vinuesa, Peter ten Dijke, and Gonzalo Sanchez‐Duffhues. Bone morphogenetic protein receptor signal transduction in human disease. The Journal of Pathology, 247:9-20, Nov 2019. URL: https://doi.org/10.1002/path.5170, doi:10.1002/path.5170. This article has 243 citations.
9. (gomez‐puerto2019bonemorphogeneticprotein pages 2-4): Maria Catalina Gomez‐Puerto, Prasanna Vasudevan Iyengar, Amaya García de Vinuesa, Peter ten Dijke, and Gonzalo Sanchez‐Duffhues. Bone morphogenetic protein receptor signal transduction in human disease. The Journal of Pathology, 247:9-20, Nov 2019. URL: https://doi.org/10.1002/path.5170, doi:10.1002/path.5170. This article has 243 citations.
10. (gomez‐puerto2019bonemorphogeneticprotein pages 5-6): Maria Catalina Gomez‐Puerto, Prasanna Vasudevan Iyengar, Amaya García de Vinuesa, Peter ten Dijke, and Gonzalo Sanchez‐Duffhues. Bone morphogenetic protein receptor signal transduction in human disease. The Journal of Pathology, 247:9-20, Nov 2019. URL: https://doi.org/10.1002/path.5170, doi:10.1002/path.5170. This article has 243 citations.
11. (guo2022crystalstructuresof pages 1-2): Jingxu Guo, B. Liu, M. Thorikay, Minmin Yu, Xiaoyan Li, Z. Tong, R. Salmon, Randy J. Read, P. ten Dijke, N. Morrell, and Wei Li. Crystal structures of bmprii extracellular domain in binary and ternary receptor complexes with bmp10. Nature Communications, May 2022. URL: https://doi.org/10.1038/s41467-022-30111-2, doi:10.1038/s41467-022-30111-2. This article has 15 citations and is from a highest quality peer-reviewed journal.
12. (hiepen2019bmpr2actsas pages 1-2): Christian Hiepen, Jerome Jatzlau, Susanne Hildebrandt, Branka Kampfrath, Melis Goktas, Arunima Murgai, Jose Luis Cuellar Camacho, Rainer Haag, Clemens Ruppert, Gerhard Sengle, Elisabetta Ada Cavalcanti-Adam, Kerstin G. Blank, and Petra Knaus. Bmpr2 acts as a gatekeeper to protect endothelial cells from increased tgfβ responses and altered cell mechanics. PLOS Biology, 17:e3000557, Dec 2019. URL: https://doi.org/10.1371/journal.pbio.3000557, doi:10.1371/journal.pbio.3000557. This article has 111 citations and is from a highest quality peer-reviewed journal.
13. (hiepen2019bmpr2actsas pages 22-24): Christian Hiepen, Jerome Jatzlau, Susanne Hildebrandt, Branka Kampfrath, Melis Goktas, Arunima Murgai, Jose Luis Cuellar Camacho, Rainer Haag, Clemens Ruppert, Gerhard Sengle, Elisabetta Ada Cavalcanti-Adam, Kerstin G. Blank, and Petra Knaus. Bmpr2 acts as a gatekeeper to protect endothelial cells from increased tgfβ responses and altered cell mechanics. PLOS Biology, 17:e3000557, Dec 2019. URL: https://doi.org/10.1371/journal.pbio.3000557, doi:10.1371/journal.pbio.3000557. This article has 111 citations and is from a highest quality peer-reviewed journal.
14. (hiepen2019bmpr2actsas pages 46-47): Christian Hiepen, Jerome Jatzlau, Susanne Hildebrandt, Branka Kampfrath, Melis Goktas, Arunima Murgai, Jose Luis Cuellar Camacho, Rainer Haag, Clemens Ruppert, Gerhard Sengle, Elisabetta Ada Cavalcanti-Adam, Kerstin G. Blank, and Petra Knaus. Bmpr2 acts as a gatekeeper to protect endothelial cells from increased tgfβ responses and altered cell mechanics. PLOS Biology, 17:e3000557, Dec 2019. URL: https://doi.org/10.1371/journal.pbio.3000557, doi:10.1371/journal.pbio.3000557. This article has 111 citations and is from a highest quality peer-reviewed journal.
15. (long2015selectiveenhancementof pages 1-2): Lu Long, Mark L Ormiston, Xudong Yang, Mark Southwood, Stefan Gräf, Rajiv D Machado, Matthias Mueller, Bernd Kinzel, Lai Ming Yung, Janine M Wilkinson, Stephen D Moore, Kylie M Drake, Micheala A Aldred, Paul B Yu, Paul D Upton, and Nicholas W Morrell. Selective enhancement of endothelial bmpr-ii with bmp9 reverses pulmonary arterial hypertension. Nature Medicine, 21:777-785, Jun 2015. URL: https://doi.org/10.1038/nm.3877, doi:10.1038/nm.3877. This article has 538 citations and is from a highest quality peer-reviewed journal.
16. (modukuri2023discoveryofhighly pages 1-2): Ram K. Modukuri, Diana Monsivais, Feng Li, Murugesan Palaniappan, Kurt M. Bohren, Zhi Tan, Angela F. Ku, Yong Wang, Chandrashekhar Madasu, Jian-Yuan Li, Suni Tang, Gabriella Miklossy, Stephen S. Palmer, Damian W. Young, and Martin M. Matzuk. Discovery of highly potent and bmpr2-selective kinase inhibitors using dna-encoded chemical library screening. Journal of Medicinal Chemistry, 66:2143-2160, Jan 2023. URL: https://doi.org/10.1021/acs.jmedchem.2c01886, doi:10.1021/acs.jmedchem.2c01886. This article has 19 citations and is from a highest quality peer-reviewed journal.
17. (song2005increasedsusceptibilityto pages 9-10): Yanli Song, John E. Jones, Hideyuki Beppu, John F. Keaney, Joseph Loscalzo, and Ying-Yi Zhang. Increased susceptibility to pulmonary hypertension in heterozygous bmpr2-mutant mice. Circulation, 112:553-562, Jul 2005. URL: https://doi.org/10.1161/circulationaha.104.492488, doi:10.1161/circulationaha.104.492488. This article has 245 citations and is from a highest quality peer-reviewed journal.
18. (teichertkuliszewska2006bonemorphogeneticprotein pages 1-3): Krystyna Teichert-Kuliszewska, Michael J.B. Kutryk, Michael A. Kuliszewski, Golnaz Karoubi, David W. Courtman, Liana Zucco, John Granton, and Duncan J. Stewart. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival. Circulation Research, 98:209-217, Feb 2006. URL: https://doi.org/10.1161/01.res.0000200180.01710.e6, doi:10.1161/01.res.0000200180.01710.e6. This article has 449 citations and is from a highest quality peer-reviewed journal.
19. (duffhuesUnknownyeardikep. pages 13-13): G Sanchez Duffhues. Di ke, p. ten.(2020). Unknown journal, Unknown year.
20. (gomez‐puerto2019bonemorphogeneticprotein pages 8-9): Maria Catalina Gomez‐Puerto, Prasanna Vasudevan Iyengar, Amaya García de Vinuesa, Peter ten Dijke, and Gonzalo Sanchez‐Duffhues. Bone morphogenetic protein receptor signal transduction in human disease. The Journal of Pathology, 247:9-20, Nov 2019. URL: https://doi.org/10.1002/path.5170, doi:10.1002/path.5170. This article has 243 citations.
21. (lowery2014nlinkedglycosylationof pages 3-4): Jonathan W. Lowery, Jose M. Amich, Alex Andonian, and Vicki Rosen. N-linked glycosylation of the bone morphogenetic protein receptor type 2 (bmpr2) enhances ligand binding. Cellular and Molecular Life Sciences, 71:3165-3172, Dec 2014. URL: https://doi.org/10.1007/s00018-013-1541-8, doi:10.1007/s00018-013-1541-8. This article has 29 citations and is from a domain leading peer-reviewed journal.